We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 31, 2021

First-Line Nivolumab Plus Low-Dose Ipilimumab for MSI-High/MMR-Deficient Metastatic Colorectal Cancer

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study
J. Clin. Oncol 2021 Oct 12;[EPub Ahead of Print], HJ Lenz, E Van Cutsem, M Luisa Limon, KYM Wong, A Hendlisz, M Aglietta, P García-Alfonso, B Neyns, G Luppi, DB Cardin, T Dragovich, U Shah, S Abdullaev, J Gricar, JM Ledeine, MJ Overman, S Lonardi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading